Recently, Schipke and colleagues proposed the combined measurement of six different blood markers, BDNF, IGF-1, VEGF, TGF-beta 1, MCP-1 and IL-18 to identify Alzheimer’s disease patients [31]. The gene discussed is CCL2; the disease is early-onset autosomal dominant Alzheimer disease.